| Name | Title | Contact Details |
|---|
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
Lyniate offers industry-leading interoperability solutions that deliver simple and seamless integration of all health data. With two Best-in-KLAS products, Lyniate Corepoint and Lyniate Rhapsody, we established a proven reputation on which we continue to build adaptable interoperability solutions that connect the healthcare ecosystem to unlock the full potential of data. We partner with providers, health plans, and health tech solutions around the world to enable rapid, reliable, and scalable interoperability, both vertically and horizontally, on-premises and in the cloud.
Adelaide Environmental Health Associates is a Brewster, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
As an integrated, not-for-profit organization, CentraCare is working to improve the lives and wellbeing of those living in Central Minnesota. CentraCare provides care through hospitals located in St. Cloud, Long Prairie, Melrose, Monticello, Paynesville and Sauk Centre with more than 25 clinics and specialty centers throughout the region. Additionally, Carris Health, a wholly-owned subsidiary of CentraCare, is comprised of Rice Memorial Hospital in Willmar, Redwood Hospital in Redwood Falls and seven clinics in the Southwest and West Central region of the state. CentraCare – St. Cloud Hospital has been a Magnet-designated hospital since 2004 and repeatedly receives national recognition for its outstanding quality measures. CentraCare provides comprehensive primary through tertiary care, CentraCare also operates numerous specialty services, including the CentraCare Heart & Vascular Center, Coborn Cancer Center and the CentraCare Kidney Program. CentraCare serves all who seek care with compassion, dignity and respect, while seeking to enhance individual and community health. Mission: CentraCare Health works to improve the health of every patient, every day. Vision: CentraCare Health will be the leader in Minnesota for quality, safety, service and value. Core Values: •Patient Centered: Serving patients above all. •Integrity: Adhering to honest and ethical practices. •Collaboration: Working jointly with others to improve health and health care. •Compassion: Serving all who seek our care with kindness, dignity, and respect. •Stewardship: Ensuring responsible use of all resources to best serve our communities.
Genova Diagnostics, Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Asheville, NC. To find more information about Genova Diagnostics, Inc, please visit www.gdx.net